Related Experiment Video
Updated: Jun 27, 2025
14:16
Fluorescence detection methods for microfluidic droplet platforms
Published on: December 10, 2011
22.2K
Development of a cloud-based flow rate tool for eNAMPT biomarker detection
Bailey C Buchanan1, Yisha Tang1, Hannah Lopez2
1Department of Biomedical Engineering, The University of Arizona, 1127 E. James E. Rogers Way, Tucson, AZ 85721, USA.
PNAS Nexus
|May 7, 2024
Summary
A rapid point-of-care test using particle immunoagglutination on paper microfluidics can detect extracellular nicotinamide phosphoribosyltransferase (eNAMPT) levels in under a minute. This assay aids in assessing inflammatory disease severity and guiding therapeutic decisions.
Area of Science:
- Biochemistry
- Biomarker Discovery
- Point-of-Care Diagnostics
Background:
- Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a biomarker for inflammatory diseases.
- Neutralizing eNAMPT with monoclonal antibodies shows therapeutic potential in preclinical models.
- Rapid point-of-care (POC) detection of eNAMPT is needed to assess anti-eNAMPT therapy efficacy.
Purpose of the Study:
- To develop and validate a rapid POC assay for quantifying eNAMPT in human samples.
- To assess the feasibility of using a paper microfluidic platform for eNAMPT detection.
- To enable timely patient stratification and therapeutic guidance.
Main Methods:
- Particle immunoagglutination assay on a paper microfluidic platform.
- Quantification via flow rate measurement analyzed by smartphone and Google Colab.
- Optimization using horizontal flow and immunoagglutination binding models.
Main Results:
- Assay detected eNAMPT in whole blood and plasma within 1 minute.
- Limit of detection: 1-20 pg/mL (0.1-0.2 ng/mL undiluted).
- Linear range: 5-40 pg/mL; distinguished low, mid, and high eNAMPT concentrations.
Conclusions:
- A low-cost, rapid POC assay for eNAMPT levels was successfully developed.
- The assay enables quick determination of eNAMPT in blood/plasma.
- This technology can aid clinical trial patient stratification and therapeutic decision-making for anti-eNAMPT treatments.
